A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients
A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients
复制标题
自体树突状细胞、细胞因子诱导的杀伤细胞和化疗联合治疗晚期非小细胞肺癌患者疗效的前瞻性研究
DOI：
10.1007/s13277-013-1132-1
复制
发表时间：
2014-02-01
期刊：
影响因子：
--
通讯作者：
Zhong, Hua
中科院分区：
文献类型：
--
作者：
Zhong, Runbo;Han, Baohui;Zhong, Hua
树突状细胞（DC）在诱导有效的抗肿瘤免疫应答中起着至关重要的作用。细胞因子诱导的杀伤（CIK）细胞是T淋巴细胞的一个亚群，具有清除癌细胞的能力。本研究旨在评估常规化疗后DC/CIK免疫治疗频率、进展时间（TTP）和晚期非小细胞肺癌患者总生存期（OS）之间的相关性。从2007年8月至2009年12月入组了60例IIIB-IV期非小细胞肺癌（NSCLC）患者，并随机分为两组。所有60例患者均接受了4个疗程的诺维本-铂（NP）化疗。在一组中，30例患者接受过继自体DC/CIK细胞输注，每30天输注两次。在另一组中，患者每30天接受两次以上的免疫治疗。比较两组患者的不良反应、TTP和OS。60例患者的中位生存期为13.80个月。1年、2年和3年总生存率分别为60.0%、21.7%和15.0%。接受两种以上免疫治疗的患者的1年、2年和3年总生存率分别为63.3%、30.0%和23.3%，接受两种免疫治疗的患者的1年、2年和3年总生存率分别为56.7%、13.3%和6.7%。两组间差异有统计学意义（P= 0.037）。与较少免疫治疗组相比，接受较多免疫治疗组的TTP显著延长，中位时间从6.2个月（95%CI，5.35-9.24）改善至7.3个月（95%CI，5.45-6.95;P= 0.034）。免疫化疗的不良反应可耐受。晚期NSCLC患者可在常规化疗后联合DC/CIK免疫治疗获益。在本研究中，两种以上的免疫疗法改善了这些患者的TTP和OS。
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB–IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine–platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P= 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35–9.24) to 7.3 months (95 % CI, 5.45–6.95;P= 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.